Rigel Pharmaceuticals Provides Update on COVID-19 Program
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that...
Source: prnewswire.com
Page 21 - Clinical Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Clinical Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Clinical Development Program Today - Breaking & Trending Today
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin),...
Source: prnewswire.com
Alkermes Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder
-- New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain -- -- Commercial Launch Planned for Fourth Quarter 2021 -- -- Company to Host Investor
Source: finanznachrichten.de
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan)...
Source: prnewswire.co.uk
Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- Webcast to be Held at 4:00 p.m. ET on Friday, June 4 - DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call
Source: finanznachrichten.de